28Limited antifungal diversity and availability are growing problems for the treatment of 29 fungal infections in the face of increasing drug resistance. The echinocandins, one of the newest 30 classes of antifungal drugs, inhibit production of a crucial cell wall component. However, these 31 compounds do not effectively inhibit the growth of the opportunistic fungal pathogen 32Cryptococcus neoformans, despite potent inhibition of the target enzyme. We therefore 33 performed a forward genetic screen to identify cellular processes that mediate the relative 34 tolerance of this organism to the echinocandin drug, caspofungin. Through these studies, we 35 identified 14 genetic mutants that enhance caspofungin antifungal activity. Rather than directly 36 affecting caspofungin antifungal activity, these mutations seem to prevent the activation of 37 various stress-induced compensatory cellular processes. For example, the pfa4Δ mutant has 38 defects in the palmitoylation and localization of many of its target proteins, including the Ras 39GTPase and the Chs3 chitin synthase which are both required for caspofungin tolerance. 40Similarly, we have confirmed the link between caspofungin treatment and calcineurin signaling 41 in this organism, but we suggest a deeper mechanism in which caspofungin tolerance is 42 mediated by multiple pathways downstream of calcineurin function. Additionally, a partial loss-43 of-function mutant of a COP9 signalosome component results in a highly caspofungin-44